Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many NICE technology appraisals have been delayed as a result of operational challenges in 2021; and if he will place in the Library a list of the affected appraisals.
The 19 topics listed as follows have been delayed as a result of operational challenges in 2021.
- Tuberous sclerosis complex (seizures) – cannabidiol; |
- Waldenstrom's macroglobulinaemia – zanubrutinib; |
- Head and neck cancer (untreated, metastatic squamous cell) - nivolumab (with ipilimumab); |
- Breast cancer (triple negative) - pembrolizumab (neoadjuvant, with chemotherapy); |
- Renal cell carcinoma (metastatic, untreated) - nivolumab (with cabozantinib); |
- Multiple sclerosis (relapsing-remitting) - diroximel fumarate; |
- Upadacitinib for treating active psoriatic arthritis after inadequate response to disease modifying anti-rheumatic drugs (DMARDs); |
- Gastric cancer (resect) - pembrolizumab (with chemotherapy and surgery); |
- Dermatitis (atopic, moderate, severe, aged 12 and over) – upadacitinib; |
- Tralokinumab for treating moderate to severe atopic dermatitis; |
- Dermatitis (atopic, moderate, severe, aged 12 and over) – abrocitinib; |
- Cough (refractory, chronic) – gefapixant; |
- Renal cell carcinoma - pembrolizumab (adjuvant); |
- Polyps (nasal), rhinosinusitis (chronic, severe) – mepolizumab; |
- Ulcerative colitis (moderate, severe) – ozanimod; |
- Ankylosing spondylitis (active) – upadacitinib; |
- Lung cancer (non-small-cell, resected) - atezolizumab (adjuvant); |
- Ankylosing spondylitis (active) – tofacitinib; and |
- Hepatocellular carcinoma (advanced, treated) - cabozantinib (review of technology appraisal 582). |